Ubsspecialtypharmamay2011 110525105547-phpapp01


Published on

Published in: Business, Technology
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Ubsspecialtypharmamay2011 110525105547-phpapp01

  1. 1. Innovative Drug Delivery Device Solutions<br />Ramin Mojdeh, Ph.D.<br />Executive Vice President and<br />Chief Operating Officer<br />UBS Specialty Pharma Conference<br />May 2011<br />
  2. 2. Cautionary Note Regarding Forward-Looking Statements <br />This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However you should not place undue reliance on any such forward looking statements as these are subject to risks and uncertainties.  Please refer to our press release and our SEC filings for more information regarding the use of forward looking statements.<br />2<br />
  3. 3. Introducing Unilife<br /><ul><li>Emerging global leader in innovative drug delivery device solutions
  4. 4. Enable and enhance delivery of drugs by pharmaceutical customers
  5. 5. Rapidly expanding pipeline being driven by customer needs
  6. 6. Unifill– world’s only prefilled platform with integrated safety
  7. 7. NASDAQ listed (UNIS) with state-of-the-art facility in York, PA</li></ul>3<br />
  8. 8. Attractive Market Trends and Opportunity<br /><ul><li>$30B Injectable drug delivery device market in2015, 12.3%CAGR
  9. 9. Large macromolecule composition of pharmaceutical pipeline
  10. 10. Safety legislation and sharps management
  11. 11. Devices drive patient acceptance, preference and adherence
  12. 12. Emerging healthcare needs of aging global population
  13. 13. Risingglobalhealthcarestandardscreatingstrongmarketpotential
  14. 14. Improved outcomes and economics with use of unit-dose and ready to administer formats
  15. 15. Trend to patients self-administration of injectable drugs
  16. 16. Patent cliff - 30 biologics with $51B sales expire by 2015</li></ul>4<br />
  17. 17. Strategic Focus<br /><ul><li>Innovative devicesolutionsforcommercialdrugs/biosimilars
  18. 18. Integratedproprietaryprimarydrug delivery devices withvalue-addfeatures
  19. 19. Target and address emerging unmet needs for pipeline drugs
  20. 20. Pharmaceuticalcollaborations – specializeddevicesfornoveldrugs
  21. 21. Targethigh-endofmarketfordifferentiateddevices, highmargins
  22. 22. Strategic sourcing of components
  23. 23. In-house manufacturing and final assembly</li></ul>5<br />
  24. 24. Customer-Driven Technology Pipeline<br /><ul><li>Technology pipeline developed in partnership with customers
  25. 25. Directly responding to emerging customer needs including:
  26. 26. Integrated primarydrugdelivery devices withvalue-addfeaturesandcustomization
  27. 27. Advanced syringe systems with integrated safety and transfer mechanisms
  28. 28. Dry drug reconstitution and delivery technologies
  29. 29. Large-volume viscous drugs delivery technologies
  30. 30. Targeted organ delivery devices
  31. 31. Multi-chamber proprietary primary containers and delivery systems
  32. 32. Reusable and disposable self administration device technologies
  33. 33. Technology portfolio can be leveraged to develop customized device concepts according to specific customer needs</li></ul>6<br />
  34. 34. 7<br />Unifill – The Leading Edge of Our Portfolio<br /><ul><li>World’s first and only prefilled syringes with integrated safety
  35. 35. Now in production
  36. 36. Controlled retraction into barrel
  37. 37. Needle locked after use for convenient, compact disposal</li></li></ul><li>Unifill as a Game Changer<br /><ul><li>Primary drug delivery device with integrated safety
  38. 38. Direct substitute for current prefill and safety prefill syringes
  39. 39. Powerful brand differentiation
  40. 40. Streamlines fill-finish and packaging process
  41. 41. Optimal protection</li></ul>2.5B Units Annually<br />Ancillary safety needle<br />+<br />Unifill Platform<br />Standard Prefill Syringe<br />Current Safety Syringe<br />Direct Substitute<br />Ancillary safety Device<br />+<br />Standard Prefill Syringe<br />Current Safety Syringe<br />8<br />
  42. 42. 9<br />Success in the Face of a Big Challenge<br />Technologysolvesatechnicalchallengemostthoughtimpossible<br />Sanofi invested $40MM for access rights to Unifill<br />Ready for initial shipment in July – well ahead of original schedule<br />Current capacity of 60MM units, planned 150MM unit line extension<br />
  43. 43. 10<br />New Paradigm in Drug-Device Development<br />Clinical Development (phase I, II, III)<br />Approval<br />Sales<br />Patient requirements<br />Drug industrialization requirements<br />Customized delivery device<br /><ul><li>Devicescustomizedtospecificrequirements ofdrugsandtargetpatients
  44. 44. Collaboration with drug companies from clinical development through commercial sales
  45. 45. Unique devices increasingly used to differentiate brands, optimize product lifecycles and enhance patient care</li></li></ul><li>Summary<br />11<br /><ul><li>Unilife - emerging global leader in innovative drug delivery devices
  46. 46. Injectable drug delivery device market is attractive and growing fast
  47. 47. Innovative, differentiated devices for pipeline drugs and biosimilars
  48. 48. Developing rich portfolio of technologies driven by customer need
  49. 49. Unifill: the 1st and only prefill syringe system with integrated safety
  50. 50. The new drug-device paradigm is to target pipeline drugs to develop total system solutions for the pharmaceutical partner
  51. 51. LaunchwithUnifill,thendrivegrowthwithsuccessive introductionsofinnovative,differentiateddevices</li>